A Retrospective Study on Azvudine in Hospitalized Elderly Patients with
COVID-19

Ruifang      Nie; Ning      Hou; Ke      Xu; Shan      Shen; Shuangshuang      Yang

doi:10.2174/0126667975276135240321054227

Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.

Abstract

Background: The ongoing 2019 novel coronavirus pneumonia pandemic continues to pose a serious threat to public health and safety. In response, numerous specific anti-SARS-CoV-2 drugs have been urgently approved for use. Azvudine has been recommended as a priority treatment for COVID-19 patients, but its efficacy and safety in elderly patients remain unexplored.

Methods: In this retrospective, single-center, observational study, we assessed the impact of Azvudine treatment on elderly hospitalized patients aged over 70 years. We analyzed parameters such as the time of SARS-CoV-2 negative conversion, clinical outcomes, length of hospital stay, and respiratory support requirements. Additionally, we compared changes in blood routine indicators, liver and kidney function indicators, and the incidence of adverse events before and after Azvudine administration to provide real-world data concerning elderly patients.

Results and Discussion: The study included 36 elderly patients aged 70 to 95 years. Following Azvudine administration, the average time for SARS-CoV-2 negative conversion was 5.15 days. Clinical outcomes revealed improvement and discharge in 74.3% of the patients, exacerbation in 5.7% of the patients, and mortality in 20% of the patients. Analysis of blood routine indicators and liver function indicators before and after medication showed no clinically significant changes. However, serum creatinine levels (Scr) demonstrated a statistically significant increase (71.12 ± 44.22 vs. 87.88 ± 57.39, p < 0.05).

Conclusion: Although correlation analysis was not conducted, limited by the small sample size and retrospective nature of the study, these findings underscore the importance of monitoring Azvudine’s impact on renal function.

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0126667975276135240321054227	Print ISSN 2666-7967
Publisher Name Bentham Science Publisher	Online ISSN 2666-7975

Coronaviruses

A Retrospective Study on Azvudine in Hospitalized Elderly Patients with COVID-19

Abstract Play Pause

Related Journals

Related Books

Abstract